	US 11,746,155 B2
	Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof
Antara Banerjee, San Diego, CA (US); Andrea Fanjul, San Diego, CA (US); Robert J. Hoey, San Diego, CA (US); Kacey Sachen, San Diego, CA (US); and Nikolai Suslov, San Diego, CA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Mar. 16, 2021, as Appl. No. 17/203,291.
Application 17/203,291 is a continuation of application No. 17/052,048, previously published as PCT/IB2019/000503, filed on Apr. 29, 2019.
Claims priority of provisional application 62/664,882, filed on Apr. 30, 2018.
Prior Publication US 2021/0198358 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/286 (2013.01) [C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

25 Claims

1. An isolated antibody or antigen-binding fragment thereof that binds human cannabinoid type 1 receptor (CB1) set forth in SEQ ID NO:1, wherein the antibody or antigen-binding fragment comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence, and wherein the antibody or antigen-binding fragment comprises six complementarity determining regions (CDRs): CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein

CDR-H1 has the amino acid sequence S-Y-T-F-T-R-Y-W (SEQ ID NO: 92);

CDR-H2 has the amino acid sequence I-D-P-Y-D-S-E-T (SEQ ID NO: 93);

CDR-H3 has the amino acid sequence A-R-S-Q-P-R-Y-Y-A-M-D-Y (SEQ ID NO: 94);

CDR-L1 has the amino acid sequence Q-E-I-S-G-F (SEQ ID NO: 98);

CDR-L2 has the amino acid sequence: A-A-S(SEQ ID NO: 99); and

CDR-L3 has the amino acid sequence: L-Q-Y-S-S-Y-P-Y-T (SEQ ID NO: 100).